Transplantation Proceedings
Volume 33, Issue 3, Supplement 1 , Pages S2-S3 , May 2001

General considerations of immunosuppressive therapies—efficacy versus toxicity

  • J.H Helderman

      Affiliations

    • Vanderbilt Transplant Center and The Nephrology Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    • Corresponding Author InformationAddress reprint requests to J. Harold Helderman, MD, Professor of Medicine, Microbiology & Immunology, Chief, Renal Transplant Medicine, Medical Director, Vanderbilt Transplant Center, Vanderbilt University Medical Center, S-3305 Medical Center North, Nashville, Tennessee 37232-2372

References 

  1. US Renal Transplant Mycophenolate Mofetil Study Group . Am J Kidney Dis. 1999;34:296
  2. European Mycophenolate Mofetil Cooperative Study Group . Lancet. 1995;345:1321
  3. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group . Transplantation. 1996;61:1029
  4. Ojo AO, Meier-Kriesche H-V, Hanson JA, et al.  Transplantation. 2000;69:2405
  5. Goral S, Helderman JH. Transplantation. 2000;69:2239
  6. Fujihara CK, Malheiros DM, Zatz R, et al.  Kidney Int. 1998;54:1510
  7. Muller V, Hamar P, Szabo A, et al.  Transplant Proc. 1998;30:982

PII: S0041-1345(01)02062-0

Transplantation Proceedings
Volume 33, Issue 3, Supplement 1 , Pages S2-S3 , May 2001

Article Tools